MYGN vs. NTLA, VIVO, HSKA, NEOG, EXEL, IONS, HALO, MDGL, ALKS, and FOLD
Should you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Heska (HSKA), Neogen (NEOG), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), and Amicus Therapeutics (FOLD). These companies are all part of the "medical" sector.
Myriad Genetics (NASDAQ:MYGN) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.
Myriad Genetics has a net margin of -30.30% compared to Intellia Therapeutics' net margin of -893.34%. Myriad Genetics' return on equity of -6.77% beat Intellia Therapeutics' return on equity.
In the previous week, Intellia Therapeutics had 2 more articles in the media than Myriad Genetics. MarketBeat recorded 7 mentions for Intellia Therapeutics and 5 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 1.43 beat Intellia Therapeutics' score of 1.02 indicating that Myriad Genetics is being referred to more favorably in the media.
Myriad Genetics has higher revenue and earnings than Intellia Therapeutics. Myriad Genetics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Myriad Genetics has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.
99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 2.1% of Myriad Genetics shares are owned by insiders. Comparatively, 3.0% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Myriad Genetics currently has a consensus price target of $25.57, suggesting a potential upside of 12.35%. Intellia Therapeutics has a consensus price target of $66.77, suggesting a potential upside of 212.30%. Given Intellia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Myriad Genetics.
Myriad Genetics received 46 more outperform votes than Intellia Therapeutics when rated by MarketBeat users. However, 69.37% of users gave Intellia Therapeutics an outperform vote while only 53.51% of users gave Myriad Genetics an outperform vote.
Summary
Myriad Genetics beats Intellia Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Myriad Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Myriad Genetics Competitors List
Related Companies and Tools
